Review article: prescribing medications in patients with cirrhosis – a practical guide
- 3 May 2013
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 37 (12) , 1132-1156
Abstract
Summary: Background: Most drugs have not been well studied in cirrhosis; recommendations on safe use are based largely on experience and/or expert opinion, with dosing recommendations often based on pharmacokinetic (PK) changes.Aim: To provide a practical approach to prescribing medications for cirrhotic patients.Methods: An indexedMEDLINEsearch was conducted using keywords cirrhosis, drug‐induced liver injury, pharmacodynamics (PDs), PKs, drug disposition and adverse drug reactions. Unpublished information from the Food and Drug Administration and industry was also reviewed.Results: Most medications have not been adequately studied in cirrhosis, and specific prescribing information is often lacking. Lower doses are generally recommended based on PK changes, but data are limited in terms of correlating PD effects with the degree of liver impairment. Very few drugs have been documented to have their hepatotoxicity potential enhanced by cirrhosis; most of these involve antituberculosis or antiretroviral agents used forHIVor viral hepatitis. Paracetamol can be used safely when prescribed in relatively small doses (2–3 g or less/day) for short durations, and is recommended as first‐line treatment of pain. In contrast,NSAIDs should be used cautiously (or not at all) in advanced cirrhosis. Proton pump inhibitors have been linked to an increased risk of spontaneous bacterial peritonitis (SBP) in cirrhosis and should be used with care.Conclusions: Most drugs can be used safely in cirrhosis, including those that are potentially hepatotoxic, but lower doses or reduced dosing frequency is often recommended, due to altered PKs. Drugs that can precipitate renal failure, gastrointestinal bleeding, SBP and encephalopathy should be identified and avoided.Keywords
This publication has 188 references indexed in Scilit:
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care & Research, 2012
- Review and management of drug interactions with boceprevir and telaprevirHepatology, 2012
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesHepatology, 2011
- Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE studyJournal of Antimicrobial Chemotherapy, 2010
- Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitroAntiviral Research, 2010
- Preventing Hepatitis B reactivation in immunosuppressed patients: Is it time to revisit the guidelines?Arthritis Care & Research, 2010
- Chronic hepatitis B: Update 2009 #Hepatology, 2009
- Opioid MetabolismMayo Clinic Proceedings, 2009
- Statins Are Associated With a Reduced Risk of Hepatocellular Carcinoma in a Large Cohort of Patients With DiabetesGastroenterology, 2009
- Lead, Mercury, and Arsenic in US- and Indian-Manufactured Ayurvedic Medicines Sold via the InternetJAMA, 2008